Peloton Therapeutics, Inc. announced the appointment of two new members to the company's Board of Directors. The new members are Helen S. Kim, former Executive Vice President of Business Development at Kite Pharma, Inc., a Gilead Company, and David D. Chang, M.D., Ph.D., who currently serves as Executive Vice President, Research & Development, and Chief Medical Officer of Kite. Both have joined as independent directors. Ms. Kim most recently served as Executive Vice President of Business Development at Kite Pharma, Inc., where she led the acquisition of Kite Pharma by Gilead in 2017. Dr. Chang held senior leadership roles at Amgen, including Vice President of Global Development and Head of Hematology-Oncology.